In laboratory studies, potential geroprotective interventions have been created: more than 400 geroprotectors, several gene and cell therapies. Their translation into medical practice is restricted, in part, due to the inability to assess clinical efficacy. Human biomarker panels are needed. Based on them, it will be able to predict the accelerated or delayed aging of an individual, track the effectiveness of procedures aimed at preventing aging, such as changing diets, lifestyles, increasing physical activity, geroprotective drugs. Aging biomarkers are an integrative qualitative and quantitative indicator of the functional state of a person and this is their key difference from the risk factors of specific age-related pathologies (type 2 diabetes, cardiovascular diseases, Alzheimer’s or Parkinson’s). In other words, aging biomarkers are indicators of a preclinical stage of father aging-related pathologies. Interventions should reverse these biomarkers to a younger state or slow down their changes with aging.